Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDP7657 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| CDP7657 | EXPERIMENTAL | CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CDP7657 | BIOLOGICAL | CDP7657 100 mg/ ml solution 30 mg/ kg initial dose 15 mg/ kg every other week 10 weeks |
| Placebo | OTHER | Placebo comparator |
Inclusion Criteria: * Patients with Systemic Lupus Erythematosus (SLE) Exclusion Criteria: * Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE) * History of chronic, recurrent, or recent severe infection * Significant hematologic abnormalities * History of cancer, heart fa...
CDP7657 is an investigational monoclonal antibody being studied for immune system diseases, specifically systemic lupus erythematosus. It is being developed by Biogen Inc. for the treatment of this autoimmune condition.
CDP7657 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in modulating the immune system in systemic lupus erythematosus.
CDP7657 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research on this investigational therapy for systemic lupus erythematosus.
CDP7657 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
CDP7657 has been studied in one completed Phase 1 clinical trial, NCT01764594, which evaluated its safety in patients with systemic lupus erythematosus. The trial enrolled 24 participants across multiple countries in Europe.
CDP7657 is the primary name for this investigational monoclonal antibody. No alternative names have been associated with this drug in the available information, so it is not known to be the same as any other marketed or investigational product.